Logos Bio Rises 7.02% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 19th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.80% compared to the previous day, showing strength, while LogosBio, a related stock drawing attention, surged by 7.02% compared to the previous day. LogosBio is known as a manufacturer of biotechnology equipment and consumables.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool RoboAlgorithm RASSI, LogosBio’s quant financial score is 22.82 points, ranking 20th within the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme, with higher growth and stability scores than the average of other related stocks. This indicates that compared to other stocks in the theme, LogosBio’s sales and net profit growth rates are relatively fast, and its ability to respond to changes in domestic and international economic environments is also favorable.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.